Détails sur le projet
Description
Breast cancer is a complex and potentially devastating illness in need of increased understanding and better treatments. By understanding the mechanisms behind breast cancer progression, we will be able to develop novel drugs that stop the spread of the cancer cells in the body. In this research project, we investigate a specific factor called ALDH1A3 and its role in promoting tumor growth and spread. ALDH1A3 is a marker for cancer stem cells, which are known for their ability to promote tumor spread to other parts of the body. Preclinical evidence has shown promise in targeting ALDH1A3 as a therapeutic strategy. When we inhibit ALDH1A3, we have observed a significant reduction in tumor growth, metastasis, and cancer stem cell activity. This suggests that ALDH1A3 may hold the key to unlocking new treatment approaches for breast cancer patients. In this project, we have identified two new ways that ALDH1A3 promotes breast cancer progression. First, we found that ALDH1A3 affects the production of small molecules called microRNAs, which play vital roles in regulating gene expression. By understanding this mechanism, we hope to gain insights into how ALDH1A3 influences the transformation of normal breast cells into cancerous ones. Secondly, we are exploring how ALDH1A3 modifies the "secretome," a collection of molecules that cells release to communicate with their surroundings. By studying the secretome, we aim to uncover how ALDH1A3 promotes a microenvironment that favors tumor growth and metastasis. Finally, we have developed a novel drug that specifically targets ALDH1A3. In cell experiments and animal models, this drug has shown promising results in halting tumor growth driven by ALDH1A3. By understanding the role of ALDH1A3 in breast cancer, we hope to develop effective targeted therapies. Our research is fueled by the desire to make a positive impact on the lives of breast cancer patients and bring us one step closer to conquering this devastating disease.
Statut | Actif |
---|---|
Date de début/de fin réelle | 9/1/23 → 8/31/28 |
Financement
- Institute of Cancer Research: 807 859,00 $ US
ASJC Scopus Subject Areas
- Cancer Research
- Oncology
- Medicine (miscellaneous)